2014 Annual Meeting of the European Association for the Study of the Liver*

April 9-13, 2014; London, UK
CCO’s independent Conference Coverage of EASL 2014 includes Capsule Summaries, expert faculty analysis of key studies, and downloadable slides.

Highlights of EASL 2014

Capsules

Twelve weeks of treatment in noncirrhotic patients proved to be highly efficacious, yielding very high SVR12 rates regardless of HCV subgenotype or previous treatment response, including in patients with previous null response to peginterferon/ribavirin.

Released: April 11, 2014

SVR4-24 rates reached 94% to 98% with 12 weeks of therapy, with no apparent additional benefit conferred by the use of ribavirin.

Released: April 12, 2014

All 4 regimens achieved similar high SVR12 rates and were safe and well tolerated, although cirrhotic patients appeared to achieve higher SVR12 rates with the 24-week regimens.

Released: April 13, 2014

In a phase II study, the regimen was efficacious and well tolerated with no toxicity-driven discontinuations.

Released: April 13, 2014

In a phase II study, to date, 96% of patients achieved SVR12 following 24 weeks of therapy, with no adverse effects on graft function.

Released: April 13, 2014

Sofosbuvir/ledipasvir was also well tolerated, with no grade 4 adverse events, 1 grade 3 adverse event, no discontinuations for toxicity, and no effect on HIV-1 RNA or CD4+ cell count.

Released: April 12, 2014

Regimen well tolerated and SVR12 rates similar regardless of 12- vs 24-week treatment duration.

Released: April 15, 2014

Extending treatment duration to 24 weeks or adding ribavirin did not increase SVR rates.

Released: April 16, 2014

SVR12 rates reached 93% to 100% regardless of treatment duration or the addition of ribavirin

Released: April 14, 2014

SVR12 rates in phase III study exceeded 80% in previous null/partial responders and cirrhotics.

Released: April 15, 2014

SVR12 rates 93% to 95% across treatment arms with fewer adverse events and laboratory abnormalities in RBV-free arms.

Released: April 12, 2014

Interim results also suggest high early virologic response rates in treatment-experienced noncirrhotic patients with genotype 4 HCV.

Released: April 13, 2014

SVR12 rates ranged from 64% to 100% following treatment with a novel all-oral regimen in patients with genotype 3 HCV, or genotype 1 HCV and decompensated cirrhosis, or genotype 1 HCV and failure on previous sofosbuvir-containing therapy.

Released: April 11, 2014

Triple DAA + ribavirin regimen was also well tolerated, with low rate of treatment discontinuation due to adverse events.

Released: April 12, 2014

High SVR rates attained with MK-5172 + MK-8742 regimens in hard-to-treat patients, regardless of HCV subgenotype and previous treatment response.

Released: April 12, 2014

In addition to high rates of on-treatment virologic suppression, other benefits included decreased necroinflammation with ALT normalization, improvements in platelet count and albumin levels, and resolution of ascites and hepatic encephalopathy.

Released: April 13, 2014

Presence of the Q80K variant at baseline in patients with genotype 1a HCV and IL28B TT genotype predicted an inferior response to treatment among previous null responders with genotype 1 HCV and METAVIR F0-F2.

Released: April 11, 2014

A 12-week regimen of sofosbuvir plus pegIFN/RBV produced higher virologic response rates overall, particularly in patients with cirrhosis, as compared with a 24-week regimen of sofosbuvir/RBV.

Released: April 16, 2014
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AbbVie
Gilead Sciences
Janssen Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?